Aerocrine, Inc. (STO:AEROB) announced that NIOX MINO, a hand-held point-of-care device for the measurement of airway inflammation, has been 510(k) cleared by the U.S. Food and Drug Administration (FDA). Physicians in the U.S. now have a highly accurate, non-invasive and convenient technology that is appropriate for use in a doctor’s office, ultimately helping them improve how they treat asthma patients.
NIOX MINO provides accurate, reproducible and immediate measurement of fractional exhaled nitric oxide (FENO), a validated method for assessing asthma-related airway inflammation. NIOX MINO is the first hand-held device to measure airway inflammation—an underlying cause of inflammatory airway diseases—helping physicians improve patient outcomes and reduce healthcare expenditures... [PDF] Aerocrine's Press Release -
